Literature DB >> 1891987

Are TNF-alpha and IL-1 beta relevant in the pathogenesis of migraine without aura?

V Covelli1, I Munno, N M Pellegrino, M Altamura, P Decandia, C Marcuccio, A Di Venere, E Jirillo.   

Abstract

Migraine without aura (MWA) is a clinical condition characterized by multiple immune deficits, which may play an important role in the pathogenesis of the disease. In this respect, previous studies have demonstrated that patients with MWA exhibit profound dysfunctions of phagocytosis and killing exerted by polymorphonuclear cells (PMN) and monocytes. This may correlate with the increased frequency of infectious processes observed in these patients. The overall results suggested to evaluate the presence of circulating cytokines (CKs) in subjects affected by MWA. In particular, the present data point out an exaggerated spontaneous release of tumor necrosis factor (TNF)-alpha in a group of MWA individuals, which correlates with detectable levels of bacterial lipopolysaccharides (LPS) in their plasma. In view of the different biological activities displayed by TNF-alpha in the host, such as effects on the nervous and vascular systems, hemodynamics modifications and demyelinating properties, the intervention of this CK in the pathogenesis of MWA will be discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1891987

Source DB:  PubMed          Journal:  Acta Neurol (Napoli)        ISSN: 0001-6276


  16 in total

Review 1.  Tumour necrosis factor gene polymorphisms and migraine: a systematic review and meta-analysis.

Authors:  Markus Schürks; Pamela M Rist; Robert Yl Zee; Daniel I Chasman; Tobias Kurth
Journal:  Cephalalgia       Date:  2011-10       Impact factor: 6.292

2.  The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with migraine without aura.

Authors:  Shahir Mazaheri; Mehrdad Hajilooi; Alireza Rafiei
Journal:  J Neurol       Date:  2006-10-24       Impact factor: 4.849

3.  [Primary headaches and the influence of inflammatory diseases of the CNS and their respective immunmodulatory therapy].

Authors:  M Empl; A Straube
Journal:  Schmerz       Date:  2007-10       Impact factor: 1.107

4.  Immunomodulatory Effect of Toll-Like Receptor-3 Ligand Poly I:C on Cortical Spreading Depression.

Authors:  Amir Ghaemi; Azadeh Sajadian; Babak Khodaie; Ahmad Ali Lotfinia; Mahmoud Lotfinia; Afsaneh Aghabarari; Maryam Khaleghi Ghadiri; Sven Meuth; Ali Gorji
Journal:  Mol Neurobiol       Date:  2014-11-23       Impact factor: 5.590

5.  Vitamin D in migraine headache: a comprehensive review on literature.

Authors:  Zeinab Ghorbani; Mansoureh Togha; Pegah Rafiee; Zeynab Sadat Ahmadi; Reyhaneh Rasekh Magham; Samane Haghighi; Soodeh Razeghi Jahromi; Maryam Mahmoudi
Journal:  Neurol Sci       Date:  2019-08-03       Impact factor: 3.307

6.  [Immunological abnormalities in migraine and cluster headache-epiphenomenon or pathogenetic factors?].

Authors:  C Heesen; F Engler
Journal:  Schmerz       Date:  1993-03       Impact factor: 1.107

7.  The serum level of inflammatory markers in chronic and episodic migraine: a case-control study.

Authors:  Fahimeh Martami; Soodeh Razeghi Jahromi; Mansoureh Togha; Zeinab Ghorbani; Maryam Seifishahpar; Atoosa Saidpour
Journal:  Neurol Sci       Date:  2018-07-15       Impact factor: 3.307

8.  Monocyte chemotactic and phagocytic responses in migraine and tension-type headache patients.

Authors:  V Gallai; P Sarchielli; A Trequattrini; M Paciaroni
Journal:  Ital J Neurol Sci       Date:  1993-03

9.  Cytokine and interleukin profile in patients with headache and COVID-19: A pilot, CASE-control, study on 104 patients.

Authors:  Javier Trigo; David García-Azorín; Álvaro Sierra-Mencía; Álvaro Tamayo-Velasco; Pedro Martínez-Paz; Eduardo Tamayo; Angel Luis Guerrero; Hugo Gonzalo-Benito
Journal:  J Headache Pain       Date:  2021-06-04       Impact factor: 7.277

Review 10.  Genetics of migraine in the age of genome-wide association studies.

Authors:  Markus Schürks
Journal:  J Headache Pain       Date:  2011-11-11       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.